Congratulations to Our New Board Officers

ASGCT Staff - May 03, 2021

Please welcome four new members of the ASGCT Board of Directors, who will take office on June 1!

We are thrilled to introduce our four newest members of the ASGCT Board of Directors! Starting June 1, these new members will serve three-year terms and the incoming Vice President will ascend through the presidential succession process before serving as ASGCT President in 2023-24.

Vice President

Jeffrey Chamberlain, Ph.D.

University of Washington

Dr. Chamberlain is a professor in the departments of neurology, medicine, and biochemistry, the McCaw Endowed Chair in Muscular Dystrophy at the University of Washington School of Medicine, and director of the Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Center of Seattle. The main focus of his research is on the muscular dystrophies with two major goals: to develop a better understanding of the molecular basis of the pathophysiology of the diseases, and to develop gene and cell therapies that will correct and treat the muscular dystrophies.

At-Large Directors

Rayne Rouce, M.D.

Baylor College of Medicine

Dr. Rouce is an assistant professor in hematology-oncology in the department of pediatrics and associate director of community engagement in the office of diversity at Baylor College of Medicine. Dr. Rouce is also a physician at Texas Children's Cancer Center where she is a member of the bone marrow transplant/stem cell transplant program. Her clinical time is spent seeing leukemia and lymphoma patients.

Hildegard Büning, Ph.D.

Hannover Medical School

Dr. Büning is a professor of infection biology and gene transfer and deputy director of the institute of experimental hematology at Hannover Medical School in Germany. Aiming to optimize efficacy, specificity, and safety of AAV vectors for gene therapy and regenerative medicine, Dr. Büning's research team is developing strategies to modify the vector tropism and immunogenicity using both rational design and library-based approaches.

At-Large Director, Clinical & Translational Council

Maria-Grazia Roncarolo, M.D.

Stanford University

Dr. Roncarolo is the George D. Smith Professor in Stem Cell and Regenerative Medicine, professor of pediatrics and of medicine, director of the Center for Definitive and Curative Medicine, and co-director of the Institute for Stem Cell Biology and Regenerative Medicine at Stanford University. She leads efforts to translate scientific discoveries in genetic diseases and regenerative medicine into novel patient therapies, including treatments based on stem cells and gene therapy.

Share This Page